In this issue of Science Signaling, Huang et al. (1) describe the role of the pathway mediated by the mitogen-activated protein kinase (MAPK) p38α in inducing infl ammation in experimental autoimmune encephalomyelitis (EAE), the mouse model for multiple sclerosis and the immunologist's favorite go-to tool for defi ning cellular mechanisms of autoimmunity. MAPKs are activated by myriad ligands and stimuli, including infl ammatory cytokines, chemokines, and pattern recognition receptors (PRRs). There are 14 mammalian MAPKs, which act primarily in three major signaling cascades, known commonly as the p38, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK) pathways (2) . The p38 MAPK pathway drives many of the acute infl ammatory events that occur after infection or injury, which lead to the rapid expression of genes whose products are involved in the innate immune response. Consequently, numerous drugs designed to block this pathway are in use or under development to treat autoimmunity, immunopathologies such as chronic obstructive pulmonary disease (COPD), or cancer (2). However, because p38 MAPKs are activated by many stimuli, delineating their roles in specifi c diseases or in particular sequences of events is challenging.
Huang et al. previously demonstrated that p38α is crucial in dendritic cells (DCs), but not T cells or macrophages, during the initiation phase of EAE (3). p38α signaling is induced in DCs by PRRs, T cell costimulation, or both and subsequently enhances the production of interleukin-6 (IL-6) but inhibits IL-27 production. These cytokines in turn promote the generation of T helper 17 (T H 17) cells. In their current study, the authors used several elegant genetic approaches to further decipher the roles of the p38α pathway in EAE and the response to the effector cytokine IL-17 in the central nervous system (CNS). Using a tamoxifeninducible knockout system (p38 CreER mice), Huang et al. demonstrated that loss of p38α at the onset of clinical disease alleviated symptoms. When EAE was induced by means of passive transfer of antigen-specific T H 17 cells [generated after immunization with the myelin oligodendrocyte glycoprotein (MOG)], p38α was required in recipient mice, again pointing to a role for p38α in the effector phase. To demonstrate a role for CNS-resident cells in EAE, the authors generated conditional knockout mice lacking p38α in Nestin + cells. The Nestin-CRE transgene is specifi c to CNS-resident cells, such as neurons, astrocytes, and oligodendrocytes. Consistently, the p38α NesCre mice showed delayed onset and reduced severity of EAE, which correlated with reduced numbers of infi ltrating immune cells. In both the p38α NesCre mice and the tamoxifen-targeted p38
CreER mice, generation of antigen-specifi c T H 1 and T H 17 cells was not impaired, nor was their activity affected ex vivo. Rather, the numbers of CNS-infi ltrating cells were reduced, correlating with a decreased production of chemokines, such as CCL5, CXCL2, and CXCL1, thus suggesting a defect in the recruitment, rather than the generation, of leukocytes (Fig. 1) .
The reduced expression of various genes encoding chemokines and infl ammatory factors seen in these mice is reminiscent of signals characteristically associated with IL-17 (4). IL-17 is well established as a critical cytokine for EAE induction. Mice made defi cient in IL-17A or its receptor IL-17RA show varying degrees of resistance to EAE induction (5) . Deletion of Act1, a critical IL-17 signaling intermediate, in CNS-resident cells also results in resistance to EAE induction, with similarly reduced chemokine production by astrocytes (6) . One note of caution is that Nestin exhibits a rather ubiquitous expression in the CNS; thus, NestinCre deletes p38α in several cell types. In the current study, Huang et al. demonstrated a clear role for p38α in astrocytes; however, whether it is required in neurons or oligodendrocytes remains uncertain.
IL-17 activates all three major MAPK pathways; however, which pathway is dominantly activated varies by cell type (7). Accordingly, Huang et al. used specifi c IL-17A neutralizing antibodies in order to confi rm a mechanistic connection between p38α and IL-17 in EAE pathogenesis. Antibodies to IL-17A partially, though not fully, reversed the phenotype. Thus, a p38α defi ciency led to reduced disease in EAE, which was due at least in part to reduced IL-17 signaling in CNS-resident cells. To demonstrate a link between p38α and IL-17 more directly, the authors cultured mouse embryonic fi broblasts (MEFs) and astrocytes derived from p38
CreER mice. IL-17-stimulated gene expression was indeed impaired in both cell types, indicating that there was an IL-17 signaling defect because of the defi ciency in p38α. CREB [adenosine 3′,5′-monophosphate (cyclic AMP) response elementbinding protein] and MAPK-activated protein kinase 2 (MK2) are direct targets of p38α, and not surprisingly, MK2 activation was impaired in response to IL-17 signaling in p38
CreER cells. In contrast, IL-17-dependent activation of CREB, nuclear factor κB (NF-κB), and ERK were not affected. How does the p38α-MK2 axis control IL-17-dependent gene expression? A major activity of MK2 is to phosphorylate tristetraprolin (TTP), an RNA-binding protein that destabilizes the mRNA encoding certain cytokines (2) . In this regard, IL-17 mediates stabilization of Cxcl1 mRNA and other chemokine transcripts, although, interestingly, in a TTP-independent manner (8) . In this setting, the authors observed no effect of p38α-defi ciency on mRNA stability, at least for selected chemokines (Cxcl1 and Cxcl2).
Activation of infl ammation must be kept in check to limit potential collateral tissue damage. In the case of the p38α pathway, MAPK phosphatase-1 MKP1 [also known as dual-specifi city phosphatase 1 (DUSP1)] is activated by MK1 and dephosphorylates p38α, serving as a feedback inhibitor (2) . As would be expected, MKP1 −/− mice (reconstituted with bone marrow from wildtype mice) had the opposite phenotype of p38α-defi cient mice, with exacerbated EAE symptoms and increased leukocyte infi ltration of the CNS. Consistent with the involvement of IL-17 in this setting, MKP-1-defi cient MEFs exhibited enhanced IL-17-dependent signaling. Therefore, both positive and negative regulation of the p38α signaling pathway contributes to immunoregulation during CNS infl ammation.
Like any good study, this work raises intriguing new questions. Although IL-17A blockade reduced the effect of p38α deletion during EAE, the disease was not fully reversed, suggesting that additional factors might be involved. The role of MKP-1 as a negative regulator is intriguing, but is MKP-1 activated in response to IL-17, or is it regulated by crosstalk from other stimuli in the environment? Another open question relates to how IL-17 regulates downstream target gene expression through p38α. Because the effect of p38α seems to be independent of mRNA stability, which transcription factors are the targets of p38α? The activator protein (AP1) complex is likely to be a target, although the AP1-binding site is dispensable for IL-17-dependent activation of the proximal promoter of at least one relevant target gene, Il6 (9) . Finally, is p38α involved in IL-17 signaling in oligodendrocytes or is its activity truly specifi c to astrocytes? Although the activation and regulation of the p38 MAPK pathway is highly complex, this work convincingly limits its functional importance to a specifi c phase and cell type during CNS infl ammation. 
